The drug will be marketed under the brand name Romvimza. With its regulatory win, Ono will now go toe-to-toe with fellow Japanese pharma Daiichi Sankyo in the tenosynovial giant cell tumor (TGCT) ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia Therapeutics as chief medical officer. Makimura most recently served in leadership ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

Daiichi Sankyo promoted Hiroyuki Okuzawa as CEO, succeeding Sunao Manabe, DVM, PhD on April 1, 2025. Astellas’ chief commercial officer Claus Zieler is set to take up the new role of chief commercial ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...